BioNTech SE (BNTX) — Institutional Holders & Catalysts

Position Trend

May 15, 2025

$10.8M

2 funds

Aug 14, 2025

$39.3M

1 fund

Nov 14, 2025

$36.4M

1 fund

Feb 17, 2026

$35.1M

1 fund

+227% total institutional value over 4 quarters

Short Interest

Shorts covering

Short Shares

3.54M

Change

-25.0%

Days to Cover

2.3

% of Float

5.3%

Settlement

Mar 13, 2026

Catalysts

Phase 2May 28, 2025Bnt165eMalaria

Phase 2Jun 30, 2025Db-1305/Bnt325Advanced Solid Tumor

Phase 2Dec 30, 2025Gen1042Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

Phase 3Q1 2026Db-1303/Bnt323HER2-positive Breast Cancer

Phase 2Mar 12, 2026Bnt164a1Tuberculosis

Phase 2Q2 2026Db-1303/Bnt323HER2-positive Advanced Solid Tumor

Phase 3May 5, 2026BNT162b2 (2025/2026 recommended SARS-Co V-2 strain)Covid-19, Sars-Cov-2 Infection

Phase 3Q2 2026Db-1303/Bnt323Metastatic Breast Cancer

Phase 3Jun 16, 2026Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram doseSARS-Co V-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

Phase 3Jul 31, 2026BNT162b2 VaccineCovid-19, Sars-Cov-2 Infection

Phase 3Jul 31, 2026BNT162b2 (2025/2026 formulation)Covid-19, Sars-Cov-2 Infection

Phase 2Q3 2026Pm8002CRC (Colorectal Cancer)

Phase 2Q4 2026RO7198457 intravenous (IV)Colorectal Cancer Stage II, Colorectal Cancer Stage III

Phase 2Q2 2027BNT327 Dose Level 1 (DL1)Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer

Phase 2Q2 2027Bnt166aMpox (Monkeypox), Smallpox, Orthopoxvirus Infection

Phase 2Q3 2027Bnt324Advanced Lung Cancer

Phase 3Aug 31, 2027GotistobartNon Small Cell Lung Cancer

Phase 2Q4 2027Db-1311Advanced Solid Tumors

Phase 2Q4 2027PumitamigPancreatic Ductal Adenocarcinoma (PDAC)

Phase 2Q4 2027Bnt3212Advanced Solid Tumor

Phase 2Jan 26, 2028Bnt116Advanced Non-Small Cell Lung Cancer

Phase 2Q1 2028PumitamigRecurrent Glioblastoma

Phase 2Q1 2028Bnt326Advanced Solid Tumor

Phase 3Q1 2028Bnt323/Db-1303Endometrial Cancer

Phase 2Q2 2028Bnt323Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

Phase 2Q3 2028BNT327 Dose Level 1 (DL1)Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers

Phase 2Q4 2028PumitamigNon-small Cell Lung Cancer

Phase 3Q4 2028PumitamigExtensive-stage Small-cell Lung Cancer

Phase 2Q1 2029Bnt326Non-small Cell Lung Cancer

Phase 3Q1 2029PumitamigNon-small Cell Lung Cancer

Phase 2Mar 7, 2029Autogene CevumeranMuscle-invasive Urothelial Carcinoma

Phase 3Q2 2029Bnt113Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

Phase 2Oct 15, 2029PumitamigHepatocellular Carcinoma (HCC)

Phase 2Nov 28, 2029PumitamigAdvanced Renal Cell Carcinoma (RCC)

Phase 3Q4 2029PumitamigBreast Neoplasms

Phase 3Feb 2, 2030PumitamigUntreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2Q2 2030Bnt329Advanced Solid Cancers

Phase 2Jun 30, 2030Db-1311/Bnt324Solid Tumors

Phase 3Sep 18, 2030PumitamigNon-small Cell Lung Cancer (NSCLC)

Phase 2Q4 2030Bnt3214Advanced Solid Tumor Cancer

Phase 3Nov 8, 2030PumitamigUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Phase 2Q4 2030Bnt314Metastatic Colorectal Cancer

Phase 2Jan 1, 2031Autogene cevumeranAdenocarcinoma, Pancreatic Ductal

Phase 3Q1 2031Bnt324Metastatic Castration-resistant Prostate Cancer

Phase 3Oct 14, 2031PumitamigNon-Small Cell Lung Cancer (NSCLC)

Position Details

Baker Bros. AdvisorsFeb 17, 2026

Shares: 368,923Value: $35.1M

Signal Note: Baker Bros. Initiates Large Position in BioNTech (BNTX)

Note: The reported position value of ~$35.1B appears to be a data error — 368,923 shares at recent BNTX prices (~$95-105) would be worth approximately $35-39M, not $35B. Analysis proceeds on the corrected ~$35M figure.

Baker Bros. opening a new position in BNTX is notable given their historically concentrated, conviction-driven approach focused on clinical-stage catalysts. BioNTech's pipeline inflection points center on its oncology portfolio — particularly BNT327 (PD-L1×VEGF bispecific) generating competitive data across NSCLC and TNBC with multiple Phase 3 readouts expected through 2025-2026, and its individualized neoantigen m

Redmile GroupEXITFeb 17, 2026

Shares: 0Value: N/A

+ 6more — see how much conviction went in

See the Full Story

BioNTech SE

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links